A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy

doi:10.1158/1078-0432.CCR-17-2507

	A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
	Song, Jiangdian 1,2,3; Shi, Jingyun 4; Dong, Di1,5 ; Fang, Mengjie1,5 ; Zhong, Wenzhao 6; Wang, Kun1,5 ; Wu, Ning 7,8; Huang, Yanqi 9; Liu, Zhenyu1,5 ; Cheng, Yue 10; Gan, Yuncui 10; Zhou, Yongzhao 10; Zhou, Ping 10; Chen, Bojiang 10; Liang, Changhong 9; Liu, Zaiyi 9; Li, Weimin 10; Tian, Jie 1,5,11
发表期刊	CLINICAL CANCER RESEARCH
	2018-08-01
卷号	24 期号:15 页码:3583-3592
文章类型	Article
摘要	Purpose: We established a CT-derived approach to achieve accurate progression-free survival (PFS) prediction to EGFR tyrosine kinase inhibitors (TKI) therapy in multicenter, stage IV EGFR-mutated non-small cell lung cancer (NSCLC) patients.
关键词	EGFR-TKI therapy
WOS标题词	Science & Technology ; Life Sciences & Biomedicine
DOI	10.1158/1078-0432.CCR-17-2507
关键词[WOS]	CELL LUNG-CANCER ; TYROSINE KINASE INHIBITORS ; OPEN-LABEL ; ACQUIRED-RESISTANCE ; PHASE-III ; 1ST-LINE ERLOTINIB ; MUTATIONS ; CHEMOTHERAPY ; TRIAL ; MULTICENTER
收录类别	SCI
语种	英语
项目资助者	Natural Science Foundation of China(81771924 ; National Key R&D Program of China(2017YFA0205200 ; Science and Technology Service Network Initiative of the Chinese Academy of Sciences(KFJ-SW-STS-160) ; Instrument Developing Project of the Chinese Academy of Sciences(YZ201502) ; Beijing Municipal Science and Technology Commission(Z171100000117023 ; Youth Innovation Promotion Association CAS ; 81501616 ; 2017YFC1308700 ; Z161100002616022) ; 61671449 ; 2017YFC1308701 ; 61231004 ; 2017YFC1309100) ; 81671854 ; 81501549)
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000440600200014
引用统计	被引频次：122[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/21847
专题	中国科学院分子影像重点实验室
作者单位	1.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing, Peoples R China 2.China Med Univ, Sch Med Informat, Shenyang, Liaoning, Peoples R China 3.Northeastern Univ, Sino Dutch Biomed & Informat Engn Sch, Shenyang, Liaoning, Peoples R China 4.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Radiol, Shanghai, Peoples R China 5.Univ Chinese Acad Sci, Beijing, Peoples R China 6.Guangdong Acad Med Sci, Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China 7.Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, PET CT Ctr, Beijing, Peoples R China 8.Peking Union Med Coll, Beijing, Peoples R China 9.Guangdong Acad Med Sci, Guangdong Gen Hosp, Dept Radiol, Guangzhou, Guangdong, Peoples R China 10.West China Hosp, Dept Resp & Crit Care Med, Chengdu, Sichuan, Peoples R China 11.Beijing Key Lab Mol Imaging, Beijing, Peoples R China
第一作者单位	中国科学院自动化研究所
推荐引用方式 GB/T 7714	Song, Jiangdian,Shi, Jingyun,Dong, Di,et al. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy[J]. CLINICAL CANCER RESEARCH,2018,24(15):3583-3592.
APA	Song, Jiangdian.,Shi, Jingyun.,Dong, Di.,Fang, Mengjie.,Zhong, Wenzhao.,...&Tian, Jie.(2018).A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.CLINICAL CANCER RESEARCH,24(15),3583-3592.
MLA	Song, Jiangdian,et al."A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy".CLINICAL CANCER RESEARCH 24.15(2018):3583-3592.

条目包含的文件		下载所有文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
song2018.pdf（1305KB）	期刊论文	作者接受稿	开放获取	CC BY-NC-SA	浏览下载